$NBIX News Article - Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) https://marketwirenews.com/news-releases/neur...59509.html
(0)
(0)
Neurocrine Biosciences (NBIX) Stock Research Links